NCT00589563 · OUTCOME

Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer · Source last updated 2014-09-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: NUMBER
Unit: participants
Interval / dispersion: Not reported
Time frame: Median Follow Up: 28 months (Range: 1-49 months)

What was measured

Participants were monitored throughout the trial (median of 28 months) for various infections/complications.

Groups in this outcome

All Patients

All patients were analyzed as a single population. Stratification by conditioning regimen was not done.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
All Patients	32

Reported measurements

Neither CMV or EBV

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Patients	16	Not reported	Not reported	Not reported	Not reported

CMV reactivation only

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Patients	9	Not reported	Not reported	Not reported	Not reported

EBV only

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Patients	3	Not reported	Not reported	Not reported	Not reported

Both CMV and EBV

Values in participants · Interval/dispersion: Not reported
Group	Value	Spread	Lower	Upper	Comment
All Patients	4	Not reported	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
value
16
title
Neither CMV or EBV
categories
measurements
group Id
OG000
value
9
title
CMV reactivation only
categories
measurements
group Id
OG000
value
3
title
EBV only
categories
measurements
group Id
OG000
value
4
title
Both CMV and EBV

denoms

counts
group Id
OG000
value
32
units
Participants

description

Participants were monitored throughout the trial (median of 28 months) for various infections/complications.

groups

description
All patients were analyzed as a single population. Stratification by conditioning regimen was not done.
id
OG000
title
All Patients

param Type

NUMBER

reporting Status

POSTED

time Frame

Median Follow Up: 28 months (Range: 1-49 months)

title

Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation

type

SECONDARY

unit Of Measure

participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice